<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4975">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02045602</url>
  </required_header>
  <id_info>
    <org_study_id>P-VCNA-001</org_study_id>
    <secondary_id>2012-005555-16</secondary_id>
    <nct_id>NCT02045602</nct_id>
  </id_info>
  <brief_title>A Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine in Patients With Advanced Solid Tumors</brief_title>
  <official_title>A Phase I, Multicenter, Open-label, Dose Escalation Study of Intravenous Administration of VCN-01 Oncolytic Adenovirus With or Without Gemcitabine in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>VCN Biosciences, S.L.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>VCN Biosciences, S.L.</source>
  <oversight_info>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety and tolerability of VCN-01 either
      administered alone or in combination with gemcitabine in patients with advanced solid
      tumors, and to determine the recommended phase II dose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study consists of two parts:

        -  Part I is a dose escalation study to determine the safety and tolerability of a single
           intravenous injection of VCN-01 alone

        -  In Part II the safety and tolerability of the two highest VCN-01 tolerable doses from
           part I will be evaluated in combination with a fixed dose of gemcitabine
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Safety and Tolerability by means of Adverse Events (AEs) and laboratory data</measure>
    <time_frame>At least 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D) by determination of highest feasible dose (MFD) and any Dose Limiting Toxicities</measure>
    <time_frame>At least 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Viral Pharmacokinetics</measure>
    <time_frame>Up to 48 h</time_frame>
    <safety_issue>No</safety_issue>
    <description>Determination of VCN-01 half-life by analyzing viral genome copies in blood</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Viral Shedding</measure>
    <time_frame>Up to day 28</time_frame>
    <safety_issue>No</safety_issue>
    <description>And at least up to 6 months follow-up in patients at the Maximum Tolerated Dose (MTD)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neutralizing antibodies anti-VCN-01</measure>
    <time_frame>30 days after end of treatment phase</time_frame>
    <safety_issue>No</safety_issue>
    <description>At least up to 6 months follow-up in patients at the MTD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary anti-tumor activity by Overall Response Rate (ORR)</measure>
    <time_frame>CT or MRI scans every 8 weeks until disease progression</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary anti-tumor activity by Progression Free Survival (PFS)</measure>
    <time_frame>CT or MRI scans every 8 weeks until disease progression</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Locally Advanced Solid Tumors</condition>
  <condition>Metastatic Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Part I: Dose Escalation, Single Agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous injection of VCN-01 oncolytic adenovirus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II: Dose Escalation, Combination</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intravenous injection of VCN-01 oncolytic adenovirus in combination with a fixed dose of Gemcitabine</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>VCN-01</intervention_name>
    <description>Genetically modified human adenovirus encoding human PH20 hyaluronidase</description>
    <arm_group_label>Part I: Dose Escalation, Single Agent</arm_group_label>
    <arm_group_label>Part II: Dose Escalation, Combination</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>1000 mg/m2 intravenous administration</description>
    <arm_group_label>Part II: Dose Escalation, Combination</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male/Female patients aged 18 years or over

          -  Patients must provide written informed consent

          -  Patients with histologically confirmed, locally advanced or metastatic solid tumors

          -  Life expectancy above 3 months

          -  Patients willing to comply with treatment follow-up

          -  ECOG Performance status 0 or 1

          -  Adequate baseline organ function (hematologic, liver, renal and nutritional)

          -  Use a reliable method of contraception in fertile men and women

        Exclusion Criteria:

          -  Active infection or other serious illness or autoimmune disease

          -  Treatment with live attenuated vaccines in the last three weeks

          -  Known chronic liver disease (liver cirrhosis, chronic hepatitis)

          -  Treatment with another investigational agent within its five half-lives prior to
             VCN-01 infusion

          -  Viral syndrome diagnosed during the two weeks before inclusion

          -  Chronic immunosuppressive therapy

          -  Concurrent malignant hematologic or solid disease

          -  Pregnancy or lactation. Patients must agree to use effective contraception or be
             surgically sterile.

          -  Patients receiving full-dose anticoagulant / antiplatelet therapy

          -  Adequate levels of neutralizing antibodies against adenovirus

          -  Patients with Li Fraumeni syndrome or with previous known retinoblastoma protein
             pathway germinal deficiency
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut Català d'Oncologia</name>
      <address>
        <city>L'Hospitalet de Llobregat, Barcelona</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramon Salazar, MD</last_name>
      <email>ramonsalazar@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Ramon Salazar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Integral Oncológico Clara Campal</name>
      <address>
        <city>Madrid</city>
        <zip>25080</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Hidalgo, MD</last_name>
      <email>mhidalgo@cnio.es</email>
    </contact>
    <investigator>
      <last_name>Manuel Hidalgo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 28, 2014</lastchanged_date>
  <firstreceived_date>January 21, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>Solid Tumors</keyword>
  <keyword>Gemcitabine</keyword>
  <keyword>Oncolytic virus</keyword>
  <keyword>Metastatic</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
